Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RZ-001 with Valganciclovir in Hepatocellular Carcinoma
NCT05595473Phase 2Active, not recruiting
- Sponsor
- Rznomics
- Start
- Jul 2022
- Primary completion
- Mar 2029
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 1
01
Overview
A Phase 2 trial of RZ-001 in hepatocellular carcinoma (HCC), sponsored by Rznomics. Started Jul 2022; status: active, not recruiting.
02
Drugs
RZ-001
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05595473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05595473.